AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer
September 29 2017 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the
appointment of Tracy Palmer Berns as chief compliance officer
effective immediately. She will report to Joseph Vittiglio, general
counsel and senior vice president of legal affairs and quality.
In her role at AMAG, Ms. Berns will be responsible for the
company’s compliance program and therapeutic-product legal team and
provide legal advice on regulatory, development, pharmacovigilance
and quality matters. Additionally, she will further strengthen the
organization’s culture to continue to prioritize ethics and
compliance.
Ms. Berns brings more than 20 years of healthcare industry
experience, creating effective compliance programs focused on
policies, training, risk assessment, monitoring, investigations and
discipline. Most recently, she served as the vice president of
ethics and compliance within the Minimally Invasive Therapies Group
at Medtronic, reporting to the president of the division and
Medtronic’s chief ethics and compliance officer.
Prior to this position, she was vice president and chief
compliance and regulatory counsel at Covidien, where she was
responsible for the company’s global compliance program to ensure
compliance with relevant laws and regulations.
“I am confident that Tracy’s broad experience leading compliance
programs in other healthcare organizations will be beneficial to
AMAG today, and in the future as we continue to expand our product
portfolio,” said Mr. Vittiglio. “Her insights and expertise will be
helpful as we continue to develop and market novel therapeutics to
address significant unmet medical needs.”
Ms. Berns received her law degree from Columbia University and
her Bachelor’s degree at Knox College in Illinois.
Inducement Equity Awards In connection with
Ms. Berns entering into employment with AMAG, the Board of
Directors of AMAG approved awards to Ms. Berns of (i) an option to
purchase 20,000 shares of common stock and (ii) 9,000 restricted
stock units. The option will have an exercise price equal to the
closing price of AMAG's common stock on the grant date and will be
exercisable in four equal annual installments beginning on the
first anniversary of the grant date. The option will have a
ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be
granted. The restricted stock units will vest in three equal annual
installments beginning on the first anniversary of the grant date
and will be subject to the restricted stock unit agreement pursuant
to which the restricted stock units will be granted. These equity
awards will be granted without stockholder approval as inducements
material to Ms. Berns entering into employment with AMAG in
accordance with NASDAQ Listing Rule 5635(c)(4).
About AMAGAMAG is a biopharmaceutical company
focused on developing and delivering important therapeutics,
conducting clinical research in areas of unmet need and creating
education and support programs for the patients and families we
serve. Our currently marketed products support the health of
patients in the areas of maternal and women’s health, anemia
management and cancer supportive care. Through CBR®, we also help
families to preserve newborn stem cells, which are used today in
transplant medicine for certain cancers and blood, immune and
metabolic disorders, and have the potential to play a valuable role
in the ongoing development of regenerative medicine. For additional
company information, please
visit www.amagpharma.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not
describe historical facts, including but not limited to statements
regarding Ms. Berns’ responsibilities at AMAG related to the
company’s compliance program and its’ therapeutic-product legal
team, including providing legal advice on regulatory, development,
pharmacovigilance and quality matters and strengthening the
organization’s culture to continue to prioritize ethics and
compliance; AMAG’s belief that Ms. Berns’ broad experience leading
compliance programs in other healthcare organizations will be
beneficial to AMAG as it continues to expand its product portfolio
and that her insights and expertise will be helpful as the company
continues to develop and market novel therapeutics to address
significant unmet medical needs; and beliefs that newborn stem
cells have the potential to play a valuable role in the development
of regenerative medicine are forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking
statements.
Such risks and uncertainties include, among others, those
identified in AMAG’s Securities and Exchange Commission (SEC)
filings, including AMAG’s Annual Report on Form 10-K for the year
ended December 31, 2016 and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® and Feraheme® are registered
trademarks of AMAG Pharmaceuticals, Inc. CBR® is a
registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals, Inc. Contacts:
Media:
Rushmie Nofsinger
Executive Director, Corporate Communications & Alliance Engagement
617-498-3332
Investors:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2023 to Apr 2024